These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35189387)

  • 1. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
    Jena A; James D; Singh AK; Dutta U; Sebastian S; Sharma V
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1456-1479.e18. PubMed ID: 35189387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis.
    Jena A; Mishra S; Deepak P; Kumar-M P; Sharma A; Patel YI; Kennedy NA; Kim AHJ; Sharma V; Sebastian S
    Autoimmun Rev; 2022 Jan; 21(1):102927. PubMed ID: 34474172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving
    Dou D; Zhang F; Deng X; Ma Y; Wang S; Ji X; Zhu X; Wang D; Zhang S; Zhao L
    Heliyon; 2023 Sep; 9(9):e19609. PubMed ID: 37810049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
    Dai C; Dong ZY; Wang YN; Huang YH; Jiang M
    Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
    Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
    Front Immunol; 2022; 13():920333. PubMed ID: 35865529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    James D; Jena A; Bharath PN; Choudhury A; Singh AK; Sebastian S; Sharma V
    Dig Liver Dis; 2022 Jun; 54(6):713-721. PubMed ID: 35382972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
    Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
    Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
    Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
    J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
    Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
    Bhurwal A; Mutneja H; Bansal V; Goel A; Arora S; Attar B; Minacapelli CD; Kochhar G; Chen LA; Brant S; Seril D
    Aliment Pharmacol Ther; 2022 May; 55(10):1244-1264. PubMed ID: 35355306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
    Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.
    Miyazaki H; Watanabe D; Ito Y; Ikeda S; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
    Indian J Gastroenterol; 2023 Oct; 42(5):701-707. PubMed ID: 37505394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
    Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
    Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis.
    Luo X; Lessomo FYN; Yu Z; Xie Y
    Front Immunol; 2023; 14():1145081. PubMed ID: 37731498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.